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Abstract
Background: Nonfunctioning pituitary macroadenoma (NFPA) is a tumour of the endocrine system that is virtually
always benign and can be difficult to detect. This case report is presented from the patient’s perspective to highlight
experiences that led to the eventual diagnosis of this condition.
Case presentation: A 48 year-old male experienced prolonged and unexplained reduced athletic performance
worsening over five years. The patient reported decreased libido, which initiated a testosterone blood test. This
confirmed reduced testosterone levels and resulted in an endocrinology referral. A subsequent dynamic contrast
MRI of the pituitary region revealed a mass. The most frequent symptoms of NFPA are visual field defects, headaches
and features of hypopituitarism (includes fatigue, dizziness, dry skin, irregular periods in women and sexual dysfunction
in men).
Conclusion: Clinicians should consider this differential diagnosis in middle-aged athletes with diminished athletic
performance from an unknown cause, test visual fields and inquire if symptoms of headaches or hypopituitarism
are present.
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Background
Chiropractors are commonly utilized by middle-aged
athletes to determine sources of reduced athletic per-
formance [1]. Such clinicians are also often consulted for
headache treatment [2]. For this reason chiropractors
need to be aware of the potential diagnosis of nonfunc-
tioning pituitary macroadenoma.
The pituitary is an endocrine (hormone-producing)
gland that is located immediately below the base of the
brain (Figs. 1 and 2) [3]. It approximates the size of a
pea and is regulated by the hypothalamus [3]. It pro-
duces hormones that impact numerous parts of the body
and stimulates all the other endocrine glands to produce
their own hormones [3]. As a result of its complex tasks,
it is frequently referred to as the ‘master gland’ [3].
Nonfunctioning pituitary macroadenoma (NFPA) is a
nearly always benign tumour of the endocrine system [3, 4].
NFPA is the most common adenoma in the pituitary gland,
accounting for 25–33 % of these tumours [5, 6]. At the time
of diagnosis, most NFPAs are macroadenomas (greater
than 1 cm in diameter) [5, 6]. The prevalence of NFPA has
been estimated at 22 cases per 100 000 in cross-sectional
studies [4]. They frequently present in those greater than
50 years of age [5], and the progression can vary widely,
with some growing slowly and others becoming rapidly
invasive [5].
The gold standard method of management of NFPA is
surgical resection of the tumour via endoscopy using a
transsphenoidal approach through the nasal cavity [4].
Prognosis for treated patients is generally very good [4].
Although NFPA is benign in nature, patients often need
individualized management, lifelong diagnostic imaging
and endocrinological monitoring [7]. This paper de-
scribes a specific case presentation around diminished
athletic performance to highlight typical features related
to NFPA from the patient perspective.
Case Presentation
History
I am a Canadian Doctor of Chiropractic and chiropractic
clinician who is sharing their experience with NFPA.
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Fortunately, through fate or luck, circumstances led to
successful management. My story starts as an age 43
male, five years prior to diagnosis. After an afternoon
nap, I arose from bed quickly and had a brief intense
pain sensed in the centre of my head. For 1 month after-
wards, I had a mild sharp pain in the centre of my head
for the first 200 m of a recreational run. I attended my
family physician for this complaint and had a neuro-
logical examination, which was normal, and I was
advised to come back if the pain returned. In hindsight,
I felt this head pain was related to the NFPA; however
this was not the typical type of headache presentation.
Over the next 5 years I noticed a slow progressive reduc-
tion in strength that corresponded to a 30 % decrease in
my weight training ability. Also, I noticed a weight gain
of 5–10 lb that was mostly abdominal which I initially
thought was attributed to “getting older”. When I ran a
competitive 5-km race which resulted in me being 2 min
and 12 s slower than the previous year despite increased
training, this prompted me to return to my family
physician.
Bloodwork was ordered. A mild anemia (normochromic
normocytic) was detected, with hemoglobin of 117 g/L
(normal 135–175 g/L), hematocrit of 0.36 L/L (normal
0.40–0.50 L/L), and red blood cell count of 3.83 x E12/L
(normal 4.50–6.00 x E12/L). Investigations to determine
the etiology of the anemia included a chest x-ray, colonos-
copy, gastroscopy and abdominal ultrasound, all of which
were normal. During this time I reported to my family
physician I was losing hair on my legs, my libido was very
low along with having acquired cold sensitivity, hot
flashes, anxiety and some noticeable hair growth on the
scalp where I had been losing hair. By chance, during the
period of when various diagnostic tests were occurring, I
attended a family medicine continuing education confer-
ence where an endocrinologist spoke of the connection
between low testosterone and a pituitary tumour. I later
discussed this possibility with my family physician and a
testosterone blood test was ordered.
Physical examination
The results of the testosterone tests showed testosterone
was nearly absent at 0.5 nmol/L (normal 8.4–28.8 nmol/L)
and bioavailable testosterone was 0.1 nmol/L (normal is
3.6–11.2 nmol/L). I was referred to an endocrinologist. A
dynamic contrast MRI of the pituitary region (specifically
the sella turcica) was ordered. A large 2.5 cm diameter
mass was discovered in my pituitary region. A subsequent
referral was made to a pituitary neurosurgical team and
a series of tests and consults were booked (further
bloodwork, neuro-opthalmology and endocrinology ap-
pointments). My bloodwork identified reduced pituitary
hormone levels, which suggested the tumour was non-
functioning. The luteinizing hormone (LH) at 0.8 IU/L
(normal male 1.7–8.6 IU/L) and follicle stimulating hor-
mone (FSH) at 1.1 IU/L (normal male 1.5–12.4 IU/L) were
also reduced. Diminished levels of these hormones were
causing my testosterone to be low, which compro-
mised hematopoiesis (i.e. the production of all types of
blood cells) and resulted in the anemia [8]. Prolactin
was elevated to 51 ug/L (normal male 4–15 ug/L) due
to the tumour stalk effect (i.e. mass effect from the
tumour on the pituitary infundibulum) [7, 9]. Thyroid
function was also compromised by the NFPA. My Free
T4 was 11 pmol/L (normal 12–22 pmol/L) and Free
T3 was 2.8 pmol/L (normal 3.1–6.8 pmol/L). I was
prescribed testosterone gel and levothyroxine medica-
tion for replacement.
While frequently affected in NFPA, the neuro-
ophthamologist concluded my visual fields were normal.
A consult with an otolaryngologist (ENT) surgeon was re-
quired to evaluate the size of my nasal cavity in prepar-
ation for the surgical endoscopy procedure. In surgery, the
endoscope is passed through the nasal cavity to make an
opening in the sphenoid sinus, to access the pituitary re-
gion allowing the neurosurgeon to remove the tumour.
This is called the transsphenoidal approach and its advan-
tages are being less invasive and no visible scaring follow-
ing neurosurgery [9].
Imaging
The neurosurgeon and the neuroradiologist reviewed my
imaging (the previous dynamic contrast MRI and a
recent CT) and had a high degree of suspicion of a
NFPA. Only after surgery and pathological sectioning of
the tumour can a confirmatory diagnosis be made.
Fig. 1 Position of the Pituitary Gland in the Head. With permission from
the Pituitary Society and licenced from Thinkstock by Getty Images
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Intervention
Prior to surgery, I received meningococcal B immuniza-
tions as ENT surgery has an eleven-fold and neurosurgery
has a seven-fold, increased risk of meningitis in the first
10 days following surgery [10]. With a MRI just before sur-
gery, adhesive stickers known as fiducial markers were at-
tached to my head. This assists the neuro-navigation of the
neurosurgeon to help orient themselves relative to the
tumour position in my head during the surgery. In the op-
erating room, my head was placed in a form-fitting cradle
for stabilization. Later, when under anesthetic, a series of
pins were screwed into my skull to further stabilize it, as
the surgeon has to be very precise during the procedure.
The entire surgical procedure typically takes up to 5 h.
Conclusions
The surgery was completed without incident and I was
returned to the recovery room after approximately 4 h. I
had a subsequent follow up with my care team one month
after surgery, where the pathological sectioning confirmed
a NFPA. This was a tremendous relief as other, more sinister
tumours were a possibility. Radiation therapy was considered
but not deemed required. Future ongoing screening recom-
mendations for recurrence includes annual MRI monitoring.
Discussion
Clinical presentation
Clinically, NFPA comprise about 80 % of all pituitary
macroadenomas [5]. It is likely there are many in the
population with undetected macroadenomas [11]. Im-
aging of the head is now commonly implemented as
part of the workup of many unrelated medical cases [5]
and as a result, pituitary lesions are often detected inci-
dentally [5]. Nonfunctioning categorizes the tumour cells
as not secreting hormones versus functioning adenomas.
This can be advantageous; but also can make discovery
difficult as there is absence of a readily identifiable syn-
drome of pituitary hormone hypersecretion often leading
to growth of these tumours for many years before dis-
covery [9]. Many cases presenting with NFPA have at
Fig. 2 Hormones of the Anterior and Posterior Pituitary Gland. TSH is thyroid stimulating hormone, ACTH is adrenocorticotropic hormone, LH is
luteinizing hormone, FSH is follicle-stimulating hormone and GH is growth hormone. With permission from the Pituitary Society and licenced
from Thinkstock by Getty Images
Bauman et al. Chiropractic & Manual Therapies  (2016) 24:12 Page 3 of 6
least some pituitary insufficiency [7]. The majority of
patients who have NFPA will seek medical attention
because of a mass effect (i.e. the growing tumour apply-
ing pressure to tissues) from the macroadenoma [9].
The main complaints or symptoms associated with mass
effect are visual field defects with or without decreased
visual acuity, unspecified headache and effects of hypo-
pituitarism (Table 1) [3]. As a result, many macroadeno-
mas are often uncovered at the optometrist [9].
Visual field defects exist in 60–70 % of patients with
NFPA at the time of suspicion of the diagnosis, which
results from pressure on the optic chiasm by the tumour
[7, 9]. Patients are usually unaware of the deficiency,
which only becomes apparent during formal visual field
testing [9]. Compression of the chiasm can result in a
symmetrical bi-temporal hemianopia (i.e. loss of the
outer field of vision in both eyes), but more commonly
there is an asymmetrical bi-temporal hemianopia or even
a unilateral temporal field defect [5, 7]. The chiropractic
clinician could test visual fields if NFPA is suspected using
the confrontation visual field test. Headache, often localized
to the brow or periorbital region, is present in 40–60 % of
all patients and is generated by increased intracranial pres-
sure and/or stretching of the dura mater [7, 12]. The neuro-
surgeon stated that NFPA, along with some other pituitary
tumours, are increasingly detected in middle-aged athletes
with reduced athletic performance and signs of hypopituit-
arism. Inquiry as to the presence of these symptoms should
be made in the patient history. As chiropractors are con-
sulted by mature athletes, NFPA should remain in their
differential diagnosis when such signs are present and a re-
ferral made to their physician with a note.
Differential diagnoses of NFPA includes craniopharyn-
giomas, germinomas, metastatic tumours and vascular
aneurysms [13]. Differential diagnoses for NFPA visual
field defects includes compressive lesions (eg, cranio-
pharyngiomas), ischemic lesions (eg, pituitary apoplexy),
inflammatory lesions (eg, multiple sclerosis), and toxic
lesions (eg, pheniprazine) [12]. Differential diagnoses of
NFPA headaches includes cluster headaches, migraine
variants and trigeminal neuralgia [14]. Fatigue could be
caused by infection, anemia, endocrinopathies (eg, dia-
betes and hypothyroidism), sleep disturbances (eg, sleep
apnea), medication side-effects, adrenal insufficiency
(usually other symptoms and signs) and malignancies
(rare) [15]. Overtraining syndrome in athletes can also
lead to fatigue [16].
Pituitary tumours can be classified by size or by func-
tion [5]. The best current diagnostic imaging method for
evaluating pituitary adenomas is MRI [7]. Size, as deter-
mined by MRI, less than 1 cm in diameter is considered
a microadenoma and those tumours greater than 1 cm
in diameter are considered a macroadenoma [5, 11].
Function is described by the detectable increase of a pi-
tuitary hormone through blood tests [5]. Therefore, if no
hormones were manufactured, the tumour is defined
nonfunctioning. These tumours may also be classified
according to immunohistochemistry [11].
NFPAs that touch the optic apparatus, without visual
dysfunction, may be followed with close ophthalmological
and radiographic monitoring, pending tumour and im-
aging characteristics [17]. Surgery should be contemplated
for those patients with concerning tumour growth, loss of
endocrinological function, a lesion close to the optic
chiasm, a desire to become pregnant, or unremitting un-
specified headaches [18].
Treatment
The majority of patients with a large NFPA should have
pituitary surgery [5, 6, 9]. Surgical morbidity and cure
rate have been found to be highly reliant on the skill of
the pituitary surgeon [7, 9, 19]. The favoured surgery is a
transsphenoidal approach, due to less associated morbid-
ity and mortality [9]. The surgical management of
Table 1 Symptoms and Signs of Pituitary Hormone Deficiency. With permission from the Pituitary Society
Pituitary Hormone Target Organs Effect of Deficiency
ACTH Adrenal glands: cortisol and DHEA Fatigue, low sodium in blood, weight loss, skin pallor
TSH Thyroid gland: thyroid hormone Fatigue, weight gain, dry skin, sensitivity to cold, constipation
LH and FSH in Women Ovaries: estrogen, progesterone;
ovulation
Loss of periods, loss of sex drive, infertility
LH and FSH in Men Testes: testosterone, sperm
production
Loss of sex drive, erectile dysfunction, impotence, infertility
GH in Children & Adolescents Bone, muscle, fat Lack of growth (height); increased body fat, failure to achieve normal peak
bone mass
GH in Adults Whole body Poor quality of life, increased body fat, decreased muscle and bone mass
PRL Breast Inability to breast feed
Oxytocin Breast, Uterus Complete deficiency could make breast feeding difficult
Antidiuretic hormone
(vasopressin)
Kidney Frequent urination (day & night), dilute urine, excessive thirst
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macroadenomas (greater than 1 cm) is precipitated by
the greater probability that these tumours will increase
in size over time leading to resultant mass effects. The
initial goals of post surgical therapy are to mitigate any
future mass effect and to return normal endocrine
function [9].
Because there is a known correlation between the se-
verity of visual loss before surgery and persisting visual
field defects after treatment, the wait time for surgery is
typically expedited [7]. Besides the improvement of vis-
ual function, full cessation of headaches is likely to occur
after surgery for NFPA [7]. During post surgical follow-
up, careful assessment and replacement of pituitary defi-
ciencies is implemented [7]. It is possible that future
advancements in the field of neurosurgery, such as endo-
scopic techniques utilizing combination with neuronavi-
gation, will further improve surgical outcomes and
improve the long-term prognosis [7].
NFPA treatment can involve single or combinations of
surgical intervention, radiotherapy or pharmacological
treatment [5]. It is essential that all options for therapy
are discussed and inclusion of surgical, endocrine and
oncology providers is often provided in a multidisciplin-
ary team setting [5]. For those adenomas less than 1 cm
in diameter and restricted to the sella, a strategy of
watchful waiting and serial MRI scans is often employed
[5]. It is necessary to have ruled out any secondary hor-
monal deficiencies to optimize quality of life [5].
Assuming hormonal normality, then close monitoring
may be all that is needed [5]. With no hormone irregu-
larity present, follow up in this instance relies upon ser-
ial screening [5]. For those adenomas larger than 1 cm
(the majority), after excluding hormone deficiencies, it
is common to proceed to surgical management [5].
These macroadenomas more commonly exert pressure
effects [5].
Pharmacological treatment of the NFPA tumour itself
is typically unsuccessful [5, 9]. Medical management is
frequently based around regular follow-up, monitoring
of visual problems and secondary hormone deficiencies
[5]. Periodically, tissue regrowth develops post surgically
and, although a repeat surgical intervention can be pur-
sued, adjunctive radiotherapy also remains a useful op-
tion [5]. Indeed, radiation therapy may be proposed if
the patient is not suited for surgery or if complete
tumour removal is not achievable [5, 20, 21]. Radiosur-
gery for NFPAs is quite effective, with usually around a
90 % success rate for tumour control [20, 21].
The greatest risk of transsphenoidal neurosurgery is
a postoperative cerebrospinal fluid leak [4]. When this
occurs, a clear fluid drips out of the nose quite stead-
ily when leaning forward. Symptoms of a leak may
also include a headache, however headache can also
be expected after the neurosurgical procedure itself.
Post-surgery, rest and avoidance of straining activities
(valsalva) is required with an anticipated return to
work in approximately 2 months.
All patients that require hydrocortisone replacement
should carry a steroid card (e.g. instructions in case of
an emergency) and participate in education about sick
day rules (sickness stress requires increased cortisol
which can no longer be produced) [5]. These sick day
rules will be advised by a physician and frequently in-
volves doubling the usual hydrocortisone dose for 1 to 3
days [22]. An adrenal crisis (acute cortisol insufficiency)
can ensue during times of illness which can be life
threatening and must be managed promptly [23]. Symp-
toms include unusual tiredness and weakness, dizziness
when standing up, nausea, vomiting, diarrhea, loss of
appetite, stomach ache and joint aches and pains [22].
Prognosis and adverse events
In NFPA, no single conclusive predictive factor has
been identified that is associated with recurrence [24].
NFPAs, with or without perceptible residual tumour,
need stratification of treatment and radiological/endo-
crinological follow-up strategies [6]. The tumour
growth-free survival rates at 5 years are 85 % with
intrasellar remnant and 49 % with extrasellar remnant
and at 10 years are 58 % with intrasellar remnant and
23 % with extrasellar remnant [6]. Fortunately, 54 % of
residual tumours will not regrow again after surgery
[6, 9]. Therefore, it is advised that MRI should be re-
peated annually in these patients [6]. Reoperation or
radiotherapy should be contemplated only when the
tumoural regrowth is confirmed, except where the ad-
enomatous residue is voluminous and close to the
optic nerves/chiasm [6]. Whether NFPAs are associ-
ated with an increased mortality or reduced lifespan is
still unknown [8].
Adverse events from a transsphenoidal approach were
linked with 1 % mortality and 5 % important complica-
tions (e.g. cerebrospinal fluid leakage, fistula, meningitis,
persistent diabetes insipidus or new visual field defect)
[4]. Olfaction may be impacted by this surgical tech-
nique [25, 26]. Of patients with visual field defects prior
to surgery, 78 % had recovery in their visual field defects
[4]. Conversely, gains in pituitary function occurred in
less than a third of the patients [4]. Complete removal of
the lesions, as evaluated by the operating surgeons,
occurs in approximately 20 % of the cases [4].
Limitations
A key limitation of this paper may be the inherent/unin-
tentional bias that the principal author may bring to the
report since it’s from the patient-perspective. This case
report may have biased observations in how the princi-
pal author recounted the details.
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Case conclusion
One month after surgery, I was able to stop taking hydro-
cortisone as my pituitary returned to producing sufficient
hormone. I was off work a total of 6 weeks. Six months
post surgery, I felt I was in excellent health, had returned
to running and strength training and my body weight had
returned to the level it was 5 years prior. The 6 month fol-
low up dynamic contrast MRI showed no definite tumour
residual. Ongoing yearly MRIs will occur to monitor for
regrowth. I will continue on testosterone and levothyrox-
ine medication indefinitely and levels monitored. Truly, I
am delighted with the outcome and decided to share the
learning experience through a case report for other clini-
cians as a patient may describe these slowly progressive
symptoms during a consultation.
Take home points
 Nonfunctioning pituitary macroadenoma can be
difficult to detect
 Vision changes, headaches and symptoms of hormone
irregularity offer clues to the tumour's presence
 Unexplained reduced performance in middle-aged
athletes may be an indicator
 Post-surgery, yearly imaging may be required to
monitor for tumour recurrence
 Life-long hormone replacement therapy may be
required
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